Skip to Content



Lawsuit Filed Against Similasan For Dangerously Defective Eye Drops

Press Release

SANTA MONICA – On Wednesday, September 27, Dovel & Luner filed a class action lawsuit against Similasan Corporation. Filed on behalf of consumers nationwide, the lawsuit alleges that various Similasan Eye Drops are dangerously defective and fail to warn consumers of the risks they pose.

The Complaint, filed in the United States District Court, Central District of California, alleges that Similasan violated California’s Unfair Competition Law, California’s False Advertising Law, California’s Legal Remedies Act, state consumer protection statutes, and breached express and implied warranties.

According to the lawsuit, “Defendant’s Eye Drops are dangerously defective, for several reasons… the Products, however, fail to warn of any of these risks.” These risks, detailed in the complaint, include the following: “First, they are unapproved drugs, and thus illegal to sell. Second, they are labeled “sterile,” when in fact they are not manufactured using processes sufficiently designed to prevent contamination. Third, they contain silver sulfate, a substance that can decrease night vision and cause irreversible eye and skin discoloration.”

An example of one of Defendant’s Products that is included in the class action.

An example of one of Defendant’s Products that is included in the class action.

The complaint adds that the Plaintiffs did not know that the eye drops were unapproved or unsafe to use. It continues, “Had they known the truth, they would not have purchased the eye drops….if other consumers knew the truth, they would immediately stop using the Eye Drops.”

“The safety and well-being of consumers should always be the highest priority for any company selling products to the public,” said Christin Cho of Dovel & Luner. “Consumers deserve to be properly informed of the potential risks of a product before they decide to make a purchase.”





Jenny Elliott

SOURCE Dovel & Luner, LLP

Related Links:

Scroll to Top of Page